4/A//SEC Filing
Kite Pharma, Inc. 4/A
Accession 0001209191-16-109312
CIK 0001510580operating
Filed
Mar 16, 8:00 PM ET
Accepted
Mar 17, 9:13 PM ET
Size
11.5 KB
Accession
0001209191-16-109312
Insider Transaction Report
Form 4/AAmended
Roberts Margo R
Chief Scientific Officer
Transactions
- Exercise/Conversion
Common Stock
2016-02-17$0.70/sh+8,625$6,038→ 17,723 total - Exercise/Conversion
Employee Stock Option (Right to Buy)
2016-02-17−8,625→ 63,750 totalExercise: $0.70Exp: 2023-10-07→ Common Stock (8,625 underlying) - Exercise/Conversion
Employee Stock Option (Right to Buy)
2016-02-17−1,007→ 31,581 totalExercise: $17.00Exp: 2024-06-18→ Common Stock (1,007 underlying) - Exercise/Conversion
Common Stock
2016-02-17$17.00/sh+1,007$17,119→ 18,730 total
Footnotes (3)
- [F1]The Form 4 is being amended to report the exercise of the same number of shares from two separate stock options. The original Form 4 incorrectly showed that the entire exercise occurred under one of the stock options.
- [F2]25% of the 150,000 shares subject to the stock option vested and became exercisable on August 19, 2014, and the remaining shares subject to the stock option vest and become exercisable in 36 monthly installments as of the last calendar day of each month following the initial vesting date.
- [F3]25% of the 50,000 shares subject to the stock option vested and became exercisable on June 19, 2015, and the remaining shares subject to the stock option vest and become exercisable in 36 monthly installments as of the last calendar day of each month following the initial vesting date.
Documents
Issuer
Kite Pharma, Inc.
CIK 0001510580
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001510580
Filing Metadata
- Form type
- 4/A
- Filed
- Mar 16, 8:00 PM ET
- Accepted
- Mar 17, 9:13 PM ET
- Size
- 11.5 KB